Obsidian Therapeutics, Inc. (OBX)
NASDAQ: OBX · Real-Time Price · USD
13.66
+0.07 (0.52%)
Oct 5, 2026, 1:37 PM EDT - Market open
Obsidian Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Obsidian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $39. The average 1-year stock price forecast is 185.51% higher than the current stock price, while the lowest is $32 (+134.26%) and the highest is $43 (+214.79%).
Price Target: $39 (+185.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Obsidian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Aug '26 | Sep '26 |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 2 | 4 |
| Buy | 0 | 0 | 1 | 1 |
| Hold | 2 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 3 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $43 | Buy | Maintains | $43 | +214.79% | Sep 29, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Initiates $32 | Buy | Initiates | $32 | +134.26% | Sep 23, 2026 |
| William Blair | William Blair | Buy Initiates $43 | Buy | Initiates | $43 | +214.79% | Sep 9, 2026 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Aug 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $42 | Buy | Initiates | $42 | +207.47% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a